Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-09-19 Capital/Financing Update
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for notes issued by Novartis Capital Corporation, detailing terms such as coupon rates, maturity dates, sizes, and other bond issuance specifics. It is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content focuses on capital raising and financing terms rather than financial results, management changes, or regulatory compliance. The document length is 4082 characters, which is relatively short and consistent with a term sheet rather than a full report. Therefore, this document fits the Capital/Financing Update category (CAP).
2012-09-19 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement dated September 18, 2012, related to Novartis Capital Corporation's offering of notes due in 2022 and 2042. It includes detailed information about the securities, interest rates, redemption terms, underwriting, and legal matters. The document references incorporation by reference of other filings and provides extensive financial and legal information typical of a prospectus supplement. This type of document is related to capital raising and financing activities, specifically a debt securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, but a full prospectus supplement with detailed terms and conditions of the offering.
2012-09-18 English
F-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form F-3ASR registration statement filed with the SEC, specifically a shelf registration statement for debt securities by Novartis AG and its finance subsidiaries. It includes a prospectus describing the terms of debt securities to be offered from time to time, with details about the registration, offering process, and legal disclaimers. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing related to capital markets and securities registration, not a financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2012-09-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It references a financial report for Q2 2012 included as Exhibit 99.1, but the text itself is a brief filing incorporating that report by reference into a Form F-3 registration statement. The document length is only 3121 characters, indicating it is a short filing rather than a full financial report. It does not contain substantive financial data or analysis itself, but rather serves as a regulatory filing to provide information to the SEC and investors. According to the rules, such filings that do not contain the full report but reference or incorporate it are classified as Regulatory Filings (RNS).
2012-09-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing new clinical data for the drug Lucentis, including study results and safety profile updates. It does not contain comprehensive financial statements or detailed financial performance data. The document is a regulatory announcement providing information about clinical study outcomes and product updates rather than a financial report or earnings release. Given the nature of the document as a regulatory filing with clinical and product information, and the absence of financial statements or management discussion, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), so it is not a brief report publication announcement. Therefore, the classification is RNS with high confidence.
2012-09-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the SEC rules. The content is a media release presenting clinical trial data and efficacy results of Novartis' COPD portfolio drugs, including QVA149, glycopyrronium bromide, and indacaterol maleate. It is not an annual or quarterly financial report, nor an earnings release. It does not contain financial statements or detailed management discussion. It is a regulatory filing providing material information to the SEC and investors about clinical trial results and product efficacy. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous reports by foreign issuers that do not fit other categories. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. However, the content is primarily a press release with clinical data rather than financial or governance information. Therefore, the best classification is Regulatory Filings (RNS).
2012-09-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.